BioPlus Co. Ltd. (099430) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of BioPlus Co. Ltd. stock KRW 3,878, price KRW 2,935, upside +32.1%, quality 40 out of 100. Rating: undervalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 2,935 KRW – 8,624 KRW · fair‑value band 2,909 KRW – 4,848 KRW · the 2,935 KRW price screens below the 3,878 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow BioPlus Co. in your weekly email
Every Wednesday you see whether BioPlus Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus " Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names.
Show moreShow less
The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms.
In addition, it offers mesotherapy products, such as skin rejuvenation products under the Kiara Reju name; Slim Slimmer, a lipolysis solution; LumiDew, a whitening solution; JuveniHill, an anti-wrinkle solution; and hair scalp care, hair treatment, hair nutrition solutions under the BelloHa and BellaChe names, as well as cosmetics comprising heparinoid essence, EGF ball, and skin care gel under the La Bella name.
The company was founded in 2003 and is based in Seongnam-si, South Korea.
Stock analysis
BioPlus Co. Ltd. (099430) currently trades at 2,935 KRW, while our model-based Fair Value estimate is 3,878 KRW, implying the stock looks roughly 24% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 10,554 KRW per share, and 7 of the 14 models we run sit above the 2,935 KRW price.
Bear case: the Economic Profit group reads lowest at 1,872 KRW, and 7 of the 14 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 2,909 KRW (bear) to 4,848 KRW (bull), the price of 2,935 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
BioPlus Co. Ltd. reported revenue of 90.9B KRW in FY2025 versus 37.4B KRW in FY2021, a compound +24.8%/yr. Reported net income was 15.0B KRW in FY2025, compounding +8.9%/yr from FY2021.
Key figures
Market cap 181B KRW (≈ $134M) Micro · P/E ratio 12.9 · P/S ratio 2.43 · EPS (TTM) 224.99 KRW · Dividend yield 2.4% · Net margin 14.0% · Return on equity 10.7% · Return on assets (EBIT) 13.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 57 out of 100 (low confidence).
What moves the price
The share trades about 54% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at 32%, 099430 screens cheaper than that median.
Fair Value models
Bear2,909 KRWFair Value 3,878 KRWBull4,848 KRW
Price 2,935 KRW · Upside +32.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (132.91 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.57/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+36.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.1%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.1%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+9.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.9%
Dividend (yield on the price)2.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.51% → 17%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 12/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside+32.1% · Top 25%
Profitability
Return on equity (12 months)10.7% · Above median
Return on assets7.0% · Above median
Net margin (12 months)18.6% · Top 25%
Operating margin (12 months)24.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)22.9% · Top 25%
Dividend yield (12 months)2.4% · Above median
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is BioPlus Co. Ltd. (099430) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 3,878 KRW versus a price of 2,935 KRW, about +32% upside (undervalued).
What is the fair value of 099430?
Our model-based fair value for BioPlus Co. Ltd. is 3,878 KRW (as of Nov 8, 2026), built from audited fundamentals. The current price: 2,935 KRW.
What is the quality score of 099430?
BioPlus Co. Ltd. has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioPlus Co. Ltd. (099430)?
Our model-based price target is the fair value of 3,878 KRW (as of Nov 8, 2026) from 14 valuation models. Cautious scenario 2,909 KRW, optimistic scenario 4,848 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the BioPlus Co. Ltd. stock forecast for 2026?
Our models put fair value at 3,878 KRW, about +32% upside versus a price of 2,935 KRW (undervalued). Cautious scenario 2,909 KRW, optimistic scenario 4,848 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of BioPlus Co. Ltd. (099430)?
BioPlus Co. Ltd. reported trailing-twelve-month revenue of about 99.2B KRW (latest available figure, as of Nov 8, 2026).
Does BioPlus Co. Ltd. pay a dividend?
BioPlus Co. Ltd. currently shows a dividend yield of 2.39% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of BioPlus Co. Ltd. (099430) and when is the ex-dividend date?
BioPlus Co. Ltd. pays a dividend of 70.00 KRW per share a year, a dividend yield of 2.4%. The last ex-dividend date was Dec 29, 2025. The payout ratio is 31.1% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of BioPlus Co. Ltd. (099430)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioPlus Co. Ltd. it is 3,878 KRW per share (as of Nov 8, 2026), against a price of 2,935 KRW. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is BioPlus Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 099430 trades below its calculated fair value: price 2,935 KRW, fair value 3,878 KRW, a gap of about +32% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 099430?
No. The price is what the market pays today (2,935 KRW); the fair value is what the company's own numbers justify (3,878 KRW). For BioPlus Co. Ltd. the two are 943.25 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is BioPlus Co. Ltd. worth?
The market values BioPlus Co. Ltd. at about 181B KRW (market capitalisation, as of Nov 8, 2026). Per share that is 2,935 KRW; our models calculate a fair value of 3,878 KRW per share.
What do the bullish and bearish scenarios say about 099430?
Our models span a range for BioPlus Co. Ltd.: cautious scenario 2,909 KRW, base 3,878 KRW, optimistic 4,848 KRW per share (as of Nov 8, 2026, price 2,935 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 099430?
BioPlus Co. Ltd. trades at a price-to-earnings ratio of 12.9 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 3,878 KRW is built from several models across several years. Other multiples: P/B 1.0, P/S 2.4, EV/EBITDA 9.8.
How solid is the balance sheet of BioPlus Co. Ltd. (099430)?
Balance-sheet figures for BioPlus Co. Ltd. (as of Nov 8, 2026): return on equity 10.7%, debt of 0.03 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 099430 from its 52-week high?
BioPlus Co. Ltd. trades at 2,935 KRW, about 54% below its 52-week high of 6,330 KRW and at the low of 2,935 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 3,878 KRW is for.
Which stocks are comparable to BioPlus Co. Ltd.?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioPlus Co. Ltd. stock attractive at the current price?
The data as of Nov 8, 2026: price 2,935 KRW, calculated fair value 3,878 KRW (+32%), Quality Score 40/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 099430 calculated?
We run BioPlus Co. Ltd. through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 3,878 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. BioPlus Co. Ltd. currently trades 24% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioPlus Co. Ltd. (099430)?
The closing price on Nov 6, 2026 was 2,935 KRW. Our model-based fair value is 3,878 KRW, about +32% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioPlus Co. Ltd. right now?
The large discount to fair value meets weak quality (40/100). That raises the risk this is a value trap rather than a bargain. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of BioPlus Co. Ltd.
How large is the market capitalisation of BioPlus Co. Ltd. (099430)?
The market capitalisation of BioPlus Co. Ltd. is 181B KRW (≈ $134M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioPlus Co. Ltd. (099430)?
The price-to-sales ratio of BioPlus Co. Ltd. is 2.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BioPlus Co. Ltd. (099430)?
Earnings per share at BioPlus Co. Ltd. are 224.99 KRW (price ÷ EPS = P/E 12.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of BioPlus Co. Ltd. (099430)?
The dividend yield of BioPlus Co. Ltd. is 2.4% (payout 31.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of BioPlus Co. Ltd. (099430)?
The net margin of BioPlus Co. Ltd. is 14.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BioPlus Co. Ltd. (099430)?
The return on equity (ROE) of BioPlus Co. Ltd. is 10.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioPlus Co. Ltd. (099430)?
On an EBIT basis the return on assets of BioPlus Co. Ltd. is 13.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioPlus Co. Ltd. (099430)?
The operating margin of BioPlus Co. Ltd. is 24.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioPlus Co. Ltd. (099430)?
Revenue at BioPlus Co. Ltd. is growing +22.9% versus a year earlier (3y avg +17.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BioPlus Co. Ltd. (099430)?
Earnings per share at BioPlus Co. Ltd. are growing +416% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does BioPlus Co. Ltd. (099430) generate?
The free cash flow of BioPlus Co. Ltd. is −33.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does BioPlus Co. Ltd. (099430) carry?
The net debt of BioPlus Co. Ltd. is 38.2B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch BioPlus Co. Ltd. in the live analysis
One click puts BioPlus Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 8, 2026